European Journal of Internal Medicine
Volume 20, Issue 5 , Pages 447-453 , September 2009

Clinical approach to lupus nephritis: Recent advances

  • C. Molino

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0532 236374; fax: +39 0532 236816.
    • ,
  • F. Fabbian

      Affiliations

    • Renal Unit, St. Anna Hospital, Ferrara, Italy
    • ,
  • C. Longhini

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, Italy

Received 11 September 2007 ,Revised 11 November 2008 ,Accepted 17 December 2008.

References 

  1. Cross J, Jayne D. Diagnosis and treatment of kidney disease. Best Pract Res Clin Rheumatol. 2005;19:785–798
  2. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10:413–424
  3. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241–250
  4. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJ Med. 1999;4:211–218
  5. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol. 2003;15:528–534
  6. Zonana-Nacach A, Barr SG, Madger LA, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43:1801–1808
  7. Bernatsky S, Ramsey-Goldman R, Clarke A. Exploring the links between systemic lupus erythematosus and cancer. Rheum Dis Clin North Am. 2005;31:387–402
  8. Cameron JJS. Clinical manifestations of lupus nephritis. In:  Lewis EJ,  Schwartz MM,  Korbet SM editor. Lupus Nephritis. Oxford: Oxford University Press; 1999;p. 159–184
  9. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000;35:904–914
  10. Cameron J. Rheumatology and the kidney. In:  Davison A,  Cameron JS,  Grunfeld JP,  Kerr DNS,  Ritz E,  Winearls CG editor. 2nd edn.. Oxford Textbook of Clinical Nephrology. 5:Oxford: Oxford University Press; 1997;p. 2709–2716Korbet SM, Lewis EJ, Schwartz MM, et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000;904–914
  11. Seligman VA, Lum RF, Olson JL, Li H, Criswell LA. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med. 2002;112:726–729
  12. Hopkinson ND, Jenkinson C, Muir KR, Doherty M, Powell RJ. Racial group, socioeconomic status, and the development of persistent proteinuria in systemic lupus erythematosus. Ann Rheum Dis. 2000;59:116–119
  13. Houng DL, Papo T, Beaufils H, Wechsler B, Blétry O, Baumelou A, et al. Renal involvement in systemic lupus erythematosus. Medicine. 1999;78:148–166
  14. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15:308–318
  15. Lea J. Lupus nephritis in African Americans. Am J Med Sci. 2002;323:85–89
  16. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science. 1998;279:1052–1054
  17. Hahn BH. Mechanisms of disease: antibodies to DNA. N Engl J Med. 1998;338:1359–1368
  18. Munoz LE, Gaipl US, Franz S, Sheriff A, Voll RE, Kalden JR, et al. SLE-a disease of clearance deficiency?. Rheumatology. 2005;44:1101–1107
  19. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 2002;46:191–201
  20. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet. 2006;38:550–555
  21. Fujii Y, Fujii K, Tanaka Y. Attempt to correct abnormal signal transduction in T lymphocytes from systemic lupus erythematosus patients. Autoimmun Rev. 2006;5:143–144
  22. Fries JW, Mendrick DL, Rennke HG. Determinants of immune complex-mediated glomerulonephritis. Kidney Int. 1988;34:333–345
  23. Berden JHM. Lupus nephritis. Kidney Int. 1997;52:538–558
  24. Schwartz MM. The pathology of lupus nephritis. Semin Nephrol. 2007;27:22–34
  25. Austin HA, Illei GG. Membranous lupus nephritis. Lupus. 2005;14:65–71
  26. Appel GB, Pirani CL, D’Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol. 1994;4:1499–1515
  27. Pirani CL, Olesnicky L. Role of electronmicroscopy in the classification in the classification of lupus nephritis. Am J Kidney Dis. 1982;2:150–163
  28. Tsumagari T, Fukmoto F, Kjnio M, Tanaka K. Incidence and significance of intrarenal vasculopathies in patients with systemic lupus erythematosus. Hum Pathol. 1985;16:43–49
  29. Banfi G, Bertani T, Boeri V, Faraggiana T, Mazzucco G, Monga G, et al. Renal vascular lesions as a marker of a poor prognosis in patients with lupus nephritis. Am J Kidney Dis. 1991;18:240–248
  30. Grishman E, Gerber MA, Churg J. Vascular lesions in lupus nephritis. Mod Pathol. 1988;1:235–241
  31. Appel GB, Williams GS, Meltzer JI, Pirani CL. Renal vein thrombosis, nephrotic syndrome, and systemic lupus erythematosus. Ann Intern Med. 1976;85:310–317
  32. Stewart Cameron J. Lupus nephritis. J Am Soc Nephrol. 1999;10:413–424
  33. Mori Y, Kishimoto N, Yamahara H, Kijima Y, Nose A, Uchiyama-Tanaka Y, et al. Predominant tubulointerstitial nephritis in a patient with systemic lupus nephritis. Clin Exp Nephrol. 2005;9:79–84
  34. O’Callaghan CA. Renal manifestations of systemic autoimmune disease: diagnosis and therapy. Best Pract Res Clin Rheumat. 2004;18:411–427
  35. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol. 1986;13:486–489
  36. Uthman I, Khamashta M. Antiphospholipid syndrome and the kidneys. Semin Arthritis Rheum. 2006;35:360–367
  37. Natejumnong C, Ruangkanchanasetr P, Aimpun P, Supaporn T. Significance of antiphospholipid antibodies in lupus nephritis. J Med Assoc Thai. 2006;89(Suppl 2):S121–S128
  38. Daugas E, Nochy D, Huong DL, Duhaut P, Beaufils H, Caudwell V, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol. 2002;13:42–52
  39. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematous (SLE) patients and non-SLE disorders. Ann Intern Med. 1990;112:682–698
  40. Huong DL, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, et al. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine. 1999;78:148–166
  41. McCluskey RT. Lupus nephritis. In:  Sommers SC editors. Kidney Pathology Decennial 1966–1975. C.T. East Norwalk: Appleton-Century-Crofts; 1999;p. 435–445
  42. Churg J, Sobin LH. Renal Disease: Classification and Atlas of Glomerular Disease, Tokyo, Igaku-Shoin. 1982;
  43. Pirani CL, Pollak VE, Schwartz FD. The reproducibility of semiquantitative analysis of renal histology. Nephron. 1964;1:230–237
  44. Morel-Maroger L, Mery JP, Droz D, Godin M, Verroust P, Kourilsky O, et al. The course of lupus nephritis: contribution of serial renal biopsies. Adv Nephrol Necker Hosp. 1976;6:79–118
  45. Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984;25:689–695
  46. Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ. Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 1993;21:374–377
  47. Corwin HL, Schwartz MM, Lewis E. The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol. 1988;8:85–93
  48. Moroni G, Pasquali S, Quaglini S, Banfi G, Casanova S, Maccario M, et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis. 1999;3:530–539
  49. Bajaj S, Albert L, Gladman DD, Urowitz MB, Hallett DC, Ritchie S. Serial renal biopsy in systemic lupus erythematosus. J Rheumatol. 2000;12:2822–2826
  50. Gunnarsson I, Sundelin B, Heimbürger M, Forslid J, van Vollenhoven R, Lundberg I, et al. Repeated renal biopsy in proliferative lupus nephritis-predictive role of serum C1q and albuminuria. J Rheumatol. 2002;4:693–699
  51. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000;5:904–914
  52. Nossent JC, Bronsveld W, Swaak AJ. Systemic lupus erythematosusIII. Observations on clinical renal involvement and follow-up of renal function: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis. 1989;48:810–816
  53. Cortés-Hernández J, Ordi-Ros J, Labrador M, Segarra A, Tovar JL, Balada E, et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus. 2003;12:287–296
  54. Moroni G, Ventura D, Riva P, Panzeri P, Quaglini S, Banfi G, et al. Antiphospholipid antibodies are associated with an increased risk of chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis. 2004;1:28–36
  55. Barr RG, Seliger S, Appel GB, Zuniga R, D'Agati V, Salmon J, et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant. 2003;18:2039–2046
  56. Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. QJM. 1989;269:779–833
  57. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol. 1994;21:2046–2051
  58. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM. 1999;4:211–218
  59. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. Nephritic flares are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int. 1996;6:2047–2053
  60. Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 2004;50:2559–2568
  61. Fraenkel L, MacKenzie T, Joseph L, Kashgarian M, Hayslett JP, Esdaile JM. Response to treatment as a predictor of long-term outcome in patients with lupus nephritis. J Rheumatol. 1994;2052–2057
  62. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;8:2550–2557
  63. Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340:741–745
  64. Austin HA, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614–619
  65. Fine Derek M. Pharmacological therapy of lupus nephritis. JAMA. 2005;293:3053–3060
  66. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;12:3934–3940
  67. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–118
  68. Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J AmSoc Nephrol. 1999;10:833–839
  69. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343:1156–1162
  70. Chan TM, Wong WS, Lau CS, Tsang EWK, Ji YL, Mok MY, et al. Prolonged follow-up of patients with diffuse proliferative lupus nephritis (DPLN) treated with prednisolone and mycophenolate mofetil (MMF). J Am Soc Nephrol. 2001;12:195A
  71. Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J. 2002;115:705–709
  72. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. N Engl J Med. 2005;21:2219–2228
  73. Chan TM, Tse KC, Tang CS, Mok MY, Li FK Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;4:1076–1084
  74. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;10:971–980
  75. Houssiau FA. Management of lupus nephritis; an update. J Am Soc Nephrol. 2004;15:2694–2704
  76. Hu W, Liu Z, Shen S, Li S, Yao X, Chen H, et al. Cyclosporine A in treatment of membranous lupus nephropathy. Chin Med J. 2003;116:1827–1830
  77. Tam LS, Li EK, Leung CB, Wong KC, Lai FM, Wang A, et al. Long-term treatment of lupus nephritis with cyclosporin A. QJM. 1998;8:573–580
  78. Ferrario L, Bellone M, Bozzolo E, Baldissera E, Sabbadini MG. Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporin A. Rhematology. 2000;39:218-210
  79. Tse KC, Lam MF, Tang SC, Tang CS, Chan TM. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus. 2007;1:46–51
  80. Moroni G, Maccario M, Banfi G, Quaglini S, Ponticelli C. Treatment of membranous lupus nephritis. Am J Kidney Dis. 1998;31:681–686
  81. Mok CC, Ying KY, Lau CS, Yim CW, Ng NW, Wong WS, et al. Treatment of pure membranous lupus nephropathy with prednisolone and azathioprine: an open label trial. Am J Kidney Dis. 2004;2:269–276
  82. Spetie DN, Tang Y, Rovin BH, Nadasdy T, Nadasdy G, Pesavento TE, et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int. 2004;6:2411–2415
  83. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004;11:3580–3590
  84. Thatayatikom A, White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev. 2006;1:18–24
  85. Bhat P, Radhakrishnan J. B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies. Kidney Int. 2008;3:261–268

PII: S0953-6205(08)00336-1

doi: 10.1016/j.ejim.2008.12.018

European Journal of Internal Medicine
Volume 20, Issue 5 , Pages 447-453 , September 2009

Article Tools